Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Biomunex Pharmaceutical.

    Client Virtual Booth

    BIOMUNEX PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Biomunex Pharmaceutical
    France Flag
    Country
    Country
    France
    Address
    Address
    14 avenue d’Eylau 75116 PARIS
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biomunex.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/biomunex-pharmaceuticals
    Twitter
    Twitter
    https://twitter.com/hashtag/biomunex?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology

    Details:

    Through a license agreement, the company will further focus on the development of BMX-500, a new immunotherapy approach in oncology, based on MAIT cell redirection, in particular for the treatment of solid neoplasm including colorectal cancer, and liver cancer.


    Lead Product(s): BMX-500

    Therapeutic Area: Oncology Product Name: BMX-500

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: Institut Curie

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement March 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer

    Details:

    OT-A201 is a first-in-class bispecific antibody, which is currently being evalauted in phase 1 clinical trials for the treatment of hematological malignancy & solid tumor.


    Lead Product(s): OT-A201

    Therapeutic Area: Oncology Product Name: OT-A201

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Onward Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 24, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Onward Therapeutics and Biomunex Ink Worldwide Exclusive License and Co-development Deal to a Bispecific Antibody for Immuno-Oncology

    Details:

    Biomunex grants the rights for Onward to pursue development, manufacture and commercialization of this first-in-class bispecific antibody. Onward and Biomunex will jointly develop the antibody during the preclinical and early clinical program.


    Lead Product(s): Bispecific antibody

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Onward Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Bispecific Antibody Program

    Details:

    Biomunex and Onward will jointly develop, in a preclinical and early clinical program (BMX-101), a ‘first-in-class’ immunotherapeutic bispecific antibody, in hematological malignancies, developed by bi- and multi-specific antibody platform BiXAb.


    Lead Product(s): BMX-101

    Therapeutic Area: Oncology Product Name: BMX-101

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Onward Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search